Ulinastatin is an immuno modulator in COVID associated cytokine storm storm: A retrospective observational study


Article PDF :

Veiw Full Text PDF

Article type :

Original Article

Author :

Smita Sharma, Gyanendra Agrawal

Volume :

2

Issue :

2

Abstract :

Background: Cytokine storm is the most life-threatening complication of COVID 19. This retrospective observational study explores efficacy of broad-spectrum serine protease inhibitor ulinastatin for treatment of COVID 19 associated cytokine storm. Materials and Methods: This retrospective observational study evaluated medical records of COVID 19 patients admitted between January 2022 and April 2022 for use of ulinastatin. A total of sixty-six patients were treated with ulinastatin along with standard care and thirty-six patients only with standard care. Conclusion: The study concludes that the use of ulinastatin is associated with favorable outcome in COVID 19 cytokine storm. Ulinastatin, the advantage over steroid is anti-inflammatory effect but no adverse effect like immunosuppression, hyperglycemia, high blood pressure and psychosis. Inflammatory markers IL6, ferritin, D dimer, CRP, LDH, NLR ratio whose testing kits are freely available are good predictors of cytokine storm.

Keyword :

Serine protease inhibitor, ARDS, COVID 19 associated cytokine storm, Ulinastatin